These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 25165191)
1. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Ars E; Bernis C; Fraga G; Martínez V; Martins J; Ortiz A; Rodríguez-Pérez JC; Sans L; Torra R; Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv95-105. PubMed ID: 25165191 [TBL] [Abstract][Full Text] [Related]
2. Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases. Review 2020. Ars E; Bernis C; Fraga G; Furlano M; Martínez V; Martins J; Ortiz A; Pérez-Gómez MV; Rodríguez-Pérez JC; Sans L; Torra R; Nefrologia (Engl Ed); 2022; 42(4):367-389. PubMed ID: 36404270 [TBL] [Abstract][Full Text] [Related]
3. Autosomal dominant policystic kidney disease, more than a renal disease. Torra R Minerva Endocrinol; 2014 Jun; 39(2):79-87. PubMed ID: 24736482 [TBL] [Abstract][Full Text] [Related]
4. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Luciano RL; Dahl NK Nephrol Dial Transplant; 2014 Feb; 29(2):247-54. PubMed ID: 24215018 [TBL] [Abstract][Full Text] [Related]
5. Autosomal dominant polycystic kidney disease: pathophysiology and treatment. McCarthy S; McMullen M ANNA J; 1997 Feb; 24(1):45-51; quiz 52-3. PubMed ID: 9146123 [TBL] [Abstract][Full Text] [Related]
6. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Spithoven EM; Kramer A; Meijer E; Orskov B; Wanner C; Caskey F; Collart F; Finne P; Fogarty DG; Groothoff JW; Hoitsma A; Nogier MB; Postorino M; Ravani P; Zurriaga O; Jager KJ; Gansevoort RT; ; ; ; ; Kidney Int; 2014 Dec; 86(6):1244-52. PubMed ID: 24827775 [TBL] [Abstract][Full Text] [Related]
7. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Shaw C; Simms RJ; Pitcher D; Sandford R Nephrol Dial Transplant; 2014 Oct; 29(10):1910-8. PubMed ID: 24737444 [TBL] [Abstract][Full Text] [Related]
8. The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan. Yen PW; Chen YA; Wang W; Mao FS; Chao CT; Chiang CK; Lin SH; Tarng DC; Chiu YW; Wu MJ; Chen YC; Kao JT; Wu MS; Lin CL; Huang JW; Hung KY Nephrology (Carlton); 2024 May; 29(5):245-258. PubMed ID: 38462235 [TBL] [Abstract][Full Text] [Related]
9. Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum. van Gulick JJ; Gevers TJ; van Keimpema L; Drenth JP Neth J Med; 2011 Sep; 69(9):367-71. PubMed ID: 21978978 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the clinical management of autosomal dominant polycystic kidney disease. Torra R F1000Res; 2019; 8():. PubMed ID: 30755792 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in management of autosomal-dominant polycystic kidney disease. Potts JW; Mousa SA Am J Health Syst Pharm; 2017 Dec; 74(23):1959-1968. PubMed ID: 29167138 [TBL] [Abstract][Full Text] [Related]
12. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Reddy BV; Chapman AB Pediatr Nephrol; 2017 Jan; 32(1):31-42. PubMed ID: 27034070 [TBL] [Abstract][Full Text] [Related]